
Is INCY (Incyte Corporation) Halal or Haram?
Incyte Corporation successfully passes all AAOIFI shariah screens, making it a compliant investment for Muslim investors. The company maintains an exceptionally low debt-to-market cap ratio of just 0.4%, well below the 33% threshold. Additionally, its interest income stands at a permissible 2.05% of revenue, comfortably under the 5% limit.
Price Chart (5D)
INCY — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-05-01 | 95.26 | 97.05 | 94.82 | 96.91 | 1.2M | +1.73% |
| 2026-04-30 | 100.33 | 100.85 | 94.93 | 95.27 | 2.4M | -5.04% |
| 2026-04-29 | 99.18 | 102.86 | 96.67 | 99.10 | 2.2M | -0.08% |
| 2026-04-28 | 94.75 | 98.36 | 92.79 | 97.74 | 2.5M | +3.16% |
| 2026-04-27 | 94.50 | 97.66 | 94.50 | 95.72 | 2.1M | +1.29% |
| 2026-04-24 | 94.95 | 95.20 | 93.63 | 94.65 | 1.1M | -0.32% |
| 2026-04-23 | 96.37 | 97.25 | 95.10 | 95.47 | 905K | -0.93% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for INCY
Business Activity
Permissible
Incyte Corporation's business passes the screening as its core focus on developing and commercializing biopharmaceutical therapeutics like JAKAFI and PEMAZYRE for oncology and blood disorders is universally permissible.
Debt / Market Cap
0.36%
Interest Income
2.05%
Cash & Securities
18.41%
About Incyte Corporation (INCY)
Incyte Corporation is a leading biopharmaceutical company focused on discovering and commercializing proprietary therapeutics for oncology and blood disorders. Its core portfolio includes widely used drugs like JAKAFI for myelofibrosis, PEMAZYRE for certain tumor types, and ICLUSIG for chronic myeloid leukemia.
For Muslim investors, Incyte represents a solid Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI screening criteria, meaning its core business operations and financial structures align perfectly with Islamic finance principles.
From a financial perspective, the company boasts an incredibly clean balance sheet, highlighted by a negligible debt-to-market cap ratio of just 0.4%. Furthermore, its cash and interest-bearing securities account for 18.4% of its market cap, and interest income remains well within the permissible limit at 2.05% of total revenue.
Since the core business of developing life-saving therapeutics is universally accepted as permissible, there is no significant scholarly debate regarding its operations. However, halal investors should periodically monitor its cash reserves and interest income to ensure they do not creep above the 5% revenue threshold during high-interest rate environments.
CEO
William J. Meury
Employees
2,617
IPO Date
1993-11-04
Headquarters
Wilmington, DE, US
Website
www.incyte.comINCY Key Financial Statistics
Revenue
$5.14B
Net Income
$1.29B
EPS (Diluted)
$6.41
Stock Price
97.74
Beta
0.86
52-Week Range
57.77-112.29
Total Debt
$69.4M
Total Equity
$5.17B
Current Ratio
3.32
INCY Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+21.2%
Prior year: $4.24B
Net Cash
$3.03B
Cash: $3.10B — Debt: $69.4M
R&D Spending
$1.98B
% of Revenue
38.6%
Frequently Asked Questions About INCY
Is INCY (Incyte Corporation) stock halal to invest in?▾
What does Incyte Corporation do?▾
What screening criteria were used for INCY?▾
Does INCY require income purification?▾
When was INCY last screened?▾
Disclaimer
This shariah compliance assessment for INCY (Incyte Corporation) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.